**Title: Massive rearrangements of cellular miRNA signatures are key drivers of hepatocyte dedifferentiation**

Volker M. Lauschke1\*, Sabine U. Vorrink1, Sabrina M. Moro1, Fatemah Reyazee1, Åsa Nordling1, Delilah F. Hendriks1, Catherine C. Bell1, Rowena Sison-Young2, B. Kevin Park2, Christopher E. Goldring2, Ewa Ellis3, Inger Johansson1, Souren Mkrtchian1, Tommy B. Andersson1,4 and Magnus Ingelman-Sundberg1

1 Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, SE-17177 Stockholm, Sweden.

2 MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Sherrington Buildings, Ashton Street, University of Liverpool, UK.

3 Department of Clinical Science, Intervention and Technology, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden

4 Cardiovascular and Metabolic Diseases Innovative Medicines, DMPK, AstraZeneca R&D, SE-431 83, Mölndal, Sweden

\* To whom correspondence should be addressed

Volker M. Lauschke, Karolinska Institutet, Department of Physiology and Pharmacology, Section of Pharmacogenetics, Nanna Svartz Väg 2, 17177 Stockholm, Sweden, Phone: +46 8524 87711, Fax: +46 8337 327, E-mail: volker.lauschke@ki.se

Sabine U. Vorrink, Karolinska Institutet, Department of Physiology and Pharmacology, Section of Pharmacogenetics, Nanna Svartz Väg 2, 17177 Stockholm, Sweden, Phone: +46 8524 87762, Fax: +46 8337 327, E-mail: sabine.vorrink@ki.se

Sabrina M. L. Moro, Karolinska Institutet, Department of Physiology and Pharmacology, Section of Pharmacogenetics, Nanna Svartz Väg 2, 17177 Stockholm, Sweden, Phone: +46 8524 87762, Fax: +46 8337 327, E-mail: sabrina.ml.moro@gmail.com

Fatemah Reyazee, Karolinska Institutet, Department of Physiology and Pharmacology, Section of Pharmacogenetics, Nanna Svartz Väg 2, 17177 Stockholm, Sweden, Phone: +46 8524 87711, Fax: +46 8337 327, E-mail: fatemah.rezayee@hotmail.se

Åsa Nordling, Karolinska Institutet, Department of Physiology and Pharmacology, Section of Pharmacogenetics, Nanna Svartz Väg 2, 17177 Stockholm, Sweden, Phone: +46 8524 87762, Fax: +46 8337 327, E-mail: asa.nordling@ki.se

Delilah F. G. Hendriks, Karolinska Institutet, Department of Physiology and Pharmacology, Section of Pharmacogenetics, Nanna Svartz Väg 2, 17177 Stockholm, Sweden, Phone: +46 8524 87711, Fax: +46 8337 327, E-mail: delilah.hendriks@ki.se

Catherine Bell, Karolinska Institutet, Department of Physiology and Pharmacology, Section of Pharmacogenetics, Nanna Svartz Väg 2, 17177 Stockholm, Sweden, Phone: +46 8524 87711, Fax: +46 8337 327, E-mail: catherine.bell@ki.se

Rowena Sison-Young, MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Sherrington Buildings, Ashton Street, University of Liverpool, Liverpool, L69 3GE, UK. Email: rowena.sison-young@liverpool.ac.uk

B. Kevin Park, MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Sherrington Buildings, Ashton Street, University of Liverpool, Liverpool, L69 3GE, UK. Email: B.K.Park@liverpool.ac.uk

Christopher E.P. Goldring, MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Sherrington Buildings, Ashton Street, University of Liverpool, Liverpool, L69 3GE, UK. Email: chrissy@liv.ac.uk

Ewa Ellis, Department of Clinical Science, Intervention and Technology, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden E mail: ewa.ellis@ki.se

Inger Johansson, Karolinska Institutet, Department of Physiology and Pharmacology, Section of Pharmacogenetics, Nanna Svartz Väg 2, 17177 Stockholm, Sweden, Phone: +46 8524 87762, Fax: +46 8337 327, E-mail: inger.johansson@ki.se

Souren Mkrtchian, Karolinska Institutet, Department of Physiology and Pharmacology, Section of Pharmacogenetics, Nanna Svartz Väg 2, 17177 Stockholm, Sweden, Phone: +46 8524 87762, Fax: +46 8337 327, E-mail: souren.mkrtchian@ki.se

Tommy B. Andersson, AstraZeneca, R&D, Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Development Biotech Unit, Pepparedsleden 1, 43183 Mölndal, Sweden, Phone: +46 317761534, Fax: +46 317763786, Email: tommy.b.andersson@astrazeneca.com

Magnus Ingelman-Sundberg, Karolinska Institutet, Department of Physiology and Pharmacology, Section of Pharmacogenetics, Nanna Svartz Väg 2, 17177 Stockholm, Sweden, Phone: +46 8524 877 35, Fax: +46 8337 327, E-mail: magnus.ingelman-sundberg@ki.se

**Corresponding author:** Volker M. Lauschke, Karolinska Institutet, Department of Physiology and Pharmacology, Section of Pharmacogenetics, Nanna Svartz Väg 2, 17177 Stockholm, Sweden, Phone: +46 8524 87711, Fax: +46 8337 327, E-mail: volker.lauschke@ki.se

**List of Abbreviations:** PHH: primary human hepatocytes; CYP: cytochrome P450; ncRNA: non-coding RNA; miRNA: micro RNA; snoRNA: small nucleolar RNA; lncRNA: long non-coding RNA; RISC: RNA-induced silencing complex; ADME: absorption, distribution, metabolism and excretion; AF: acriflavine; PLL: poly-L-lysine.

**Keywords:** miRNA, transcriptomics, primary human hepatocytes, cytochrome P450, drug metabolism

**Conflict of interest**: V.M.L. and M.I.-S. are founders and owners of HepaPredict AB.

**Financial support**: This work was supported by grants from AstraZeneca, The Swedish Research Council and by the European Community under the Innovative Medicine Initiative project MIP-DILI [grant agreement number 115336]. V.M.L. was supported by a MarieCurie IEF fellowship for career development in the context of the European FP7 framework program and by a grant from the Eva och Oscar Ahrèns Stiftelse.

**Electronic Word Count**: 5994 words

**Abstract**

Hepatocytes are dynamic cells that upon injury can alternate between non-dividing differentiated and dedifferentiated proliferating states *in vivo*. However, in 2D cultures primary human hepatocytes rapidly dedifferentiate resulting in the loss of hepatic functions which significantly limits their usefulness as *in vitro* model of liver biology, liver diseases as well as drug metabolism and toxicity. Thus, understanding the underlying mechanisms and stalling of the dedifferentiation process would be highly beneficial to establish more accurate and relevant long-term *in vitro* hepatocyte models. Here, we present comprehensive analyses of whole proteome and transcriptome dynamics during the initiation of dedifferentiation during the first 24 hours of culture. We report that early major rearrangements of the non-coding transcriptome, hallmarked by increased expression of snoRNAs, lncRNAs, miRNAs, and ribosomal genes, precede most changes in coding genes during dedifferentiation of primary human hepatocytes and we speculated that these modulations could drive the hepatic dedifferentiation process. To functionally test this hypothesis, we globally inhibited the miRNA machinery using two established chemically-distinct compounds, acriflavine and poly-L-lysine. These inhibition experiments resulted in a significantly impaired miRNA response and, most importantly, in a pronounced reduction in the downregulation of hepatic genes with importance for liver function. Thus, we provide strong evidence for the importance of ncRNAs, in particular miRNAs, in hepatic dedifferentiation, which can aid the development of more efficient differentiation protocols for stem cell-derived hepatocytes and broaden our understanding of the dynamic properties of hepatocytes with respect to liver regeneration.

**Conclusion**: miRNAs are important drivers of hepatic dedifferentiation and our results providevaluable information regarding the mechanisms behind liver regeneration and possibilities to inhibit dedifferentiation *in vitro*.

**Introduction**

Upon liver injury, hepatic cells proliferate and rapidly regenerate large parts of the damaged organ *in vivo*1. Different mechanisms of liver regeneration have been described in different injury models. Under most injuries, such as partial hepatectomy, the liver regenerates by self-duplication of hepatocytes2. Yet, when hepatocyte proliferation is compromised, the formation of duct-like “oval cells” with a mixed mesenchymal and epithelial expression signature has been observed3. These progenitor cells are assumed to originate from the terminal branches of the intrahepatic biliary system4 and seminal work demonstrated that these cells can give rise to hepatocytes5. Yet, recent studies in mouse models of chronic liver insults indicated that new hepatocytes originated from pre-existing hepatocytes rather than from distinguished non-parenchymal stem-cell populations6,7. One explanation for this ostensible discrepancy might be the capacity of hepatocytes to undergo reversible ductal metaplasia, which opens the possibility that hepatocyte-derived progenitor cells expressing biliary markers are mistaken for progenitor cells of biliary origin8,9.

*In vitro* in 2D monolayer cultures, primary human hepatocytes (PHH) rapidly lose their phenotype and dedifferentiate into fetal-like progenitor states with drastically reduced liver-specific functionality, which hampers their usefulness for studies of liver biology, liver disease, drug metabolism and toxicity10,11. Most importantly, PHH rapidly lose expression of important liver-specific genes, such as cytochrome P450 (CYP) enzymes, phase 2 enzymes and transporters12. Therefore, decipherment and eventual inhibition of the dedifferentiation process could allow for more accurate and relevant long-term *in vitro* hepatocyte models. Furthermore, mechanistic understanding of the dedifferentiation process can guide the development of more efficient differentiation protocols for stem cell-derived hepatocytes. Until now however, the molecular cues that initiate the dedifferentiation process and its mediators that render hepatocytes capable to respond so rapidly to a changing cellular environment have remained elusive.

Changes in transcript levels can be modulated by non-coding (nc)RNA species such as micro (mi)RNAs, small nucleolar (sno)RNAs, and long non-coding (lnc)RNAs13. miRNAs are short single-stranded RNAs that associate with the RNA-induced silencing complex (RISC) by binding to AGO proteins, downregulating protein output of complementary transcripts by translational inhibition or transcript degradation14. An *in silico* study using 79 human livers showed that levels of 275 miRNAs correlated inversely with expression patterns of their putative hepatic target genes15. Furthermore, analyses of miRNA expression during the differentiation of stem cells to hepatocyte-like cells implicated dozens of miRNAs in these developmental programs16. Yet, miRNA dynamics during hepatocyte dedifferentiation remain to be elucidated. Combined, these data suggest that miRNAs are of paramount importance for liver function and hepatic differentiation and merit detailed investigation.

snoRNAs guide modifications of other ncRNA species such as ribosomal RNAs, thereby contributing to the remodeling of the cell’s translational capabilities17,18. Furthermore, many snoRNAs harbor sno-derived (sd)RNAs that are commonly conserved across species from vertebrates to plants19. Interestingly, some sdRNAs have been shown to impact alternative splicing and are implicated in disease (e.g. SNORD115 in Prader-Willi syndrome20), while others control levels of target mRNAs21,22.

lncRNAs are a rapidly growing class of ncRNAs that can influence protein output by regulating transcription of nearby or distal genes, impacting splicing, RNA stability or translation, as well as acting as miRNA decoys (see 23 and references therein). lncRNAs are difficult to study *en bloc* because (i) they cannot be predicted solely on their sequence and (ii) the functionality and molecular mode of action of most lncRNA family members remains poorly understood.

While mounting evidence indicates important roles for ncRNAs in hepatic dedifferentiation, their dynamics and functional effects have not been quantitatively assessed with high temporal resolution. Therefore, we here thoroughly characterized changes in coding and non-coding transcriptomes during dedifferentiation of PHH using unsupervised whole transcriptome analyses. We detected massive alterations of ncRNA signatures that preceded changes in coding transcripts during later stages of dedifferentiation. In order to investigate whether these ncRNA modulations could drive the dedifferentiation process, we established a miRNA inhibition assay using two chemically-distinct inhibitors that interfere with different nodes of the miRNA-processing pathway. We found that miRNA inhibition significantly reduced the early miRNA response and the loss of hepatic marker genes. Moreover, whole-transcriptome analyses revealed that gene expression changes during dedifferentiation in inhibitor-treated samples were globally reduced, thus providing strong evidence for the importance of ncRNAs, in particular miRNAs, in hepatic dedifferentiation.

**Materials and Methods**

**Hepatocytes cultures**

Fresh hepatocytes obtained from patients subject to liver resections at Huddinge University Hospital, Stockholm, Sweden were used for the dedifferentiation experiments (Table 1). The hepatocytes obtained from patient livers were isolated as previously described24. Use of liver specimens was approved by the Ethics Committee at Karolinska Institutet and written informed consent was obtained from all donors of liver material. Hepatocytes were seeded into plates coated with 5 μg/cm2 Rat Tail Collagen Type I (Corning) in culture medium (Williams E medium supplemented with 2mM L-glutamine, 100 units/ml penicillin, 100 µg/ml streptomycin, 10 µg/ml insulin, 5.5 µg/ml transferrin, 6.7 ng/ml sodium selenite, 100nM dexamethasone) with 10% FBS. After two hours of attachment, the medium was replaced with serum-free culture medium. Time point 0 (t0) is defined as immediately before plating. The other time points denote time passed since plating.

**miRNA inhibition experiments**

Cryopreserved hepatocytes were thawed according to the supplier’s protocol (BioreclamationIVT) and cultured as above. Cells were treated with 2 (low), 10 (medium) or 30 µM (high) AF or 1 (low), 5 (medium) or 15 µM (high) PLL as indicated.

**Statistical analyses**

Unsupervised hierarchical clustering and principal component analysis of genes was performed in Qlucore Omics Explorer 3.2. Differentially expressed genes were determined using an F-test across all time points (omnibus ANOVA). Multiple testing correction was performed using the Benjamini-Hochberg algorithms with a false discovery rate (FDR) of 1%. For correlations between mRNA and protein responses, Pearson correlation coefficients were computed on fold changes of mRNA and protein abundances at the respective time points relative to t0. Pathway analyses were performed using Ingenuity Pathway Analysis (IPA, QIAgen). Global gene expression data from control and AF/PLL-treated PHH were used to extract miRNA expression levels that were further normalized to t0. Corresponding fold-change values for upregulated miRNAs were interpreted in the microRNA Target Filter of IPA to find corresponding downregulated mRNA targets from whole transcriptome data of the same samples. Resulting gene lists were submitted to the WebGestalt online resource for KEGG pathway analysis25.

*Extended methods are available in the Supporting Information online.*

**Results**

**Transcriptomic changes occur in two distinct phases of molecular remodeling during hepatocyte dedifferentiation.**

To decode the changes in transcriptional profiles during dedifferentiation of PHH we assessed gene expression dynamics using whole transcriptome approaches in which coding as well as non-coding RNA transcripts were analyzed with high temporal resolution (n=3-5 livers per time point). In total, we identified 4,042 transcripts that were significantly differentially expressed during the first 24 hours of dedifferentiation after multiple testing correction (FDR=0.01, Figure 1A). Importantly, we detected two distinct phases of transcriptomic changes: an early response (from 30 minutes until 4 hours) and a late response (between 16 and 24 hours) that were characterized by changes in two distinctively different sets of genes (Figure 1B).

Pathway analyses of differentially expressed transcripts over time revealed significant modulations of cytokine and signal transduction pathways such as IL-1 and PKA signaling as well as PPARα/RXRα transcriptional responses already after 30 minutes followed by major restructuring of metabolic pathways evidenced by changes in oxidative phosphorylation and mitochondrial dysfunction (Figure 1C and Supporting Table 2). The earliest responses were detected in genes involved in innate immunity, whereas expression changes in genes involved in absorption, distribution, metabolism and excretion (ADME) of drugs as well as cell adhesion were found at later phases (Supporting Figure 1). Furthermore, alterations in EIF2 signaling and protein ubiquitination pathways suggest modulations of protein turnover. Significant changes at later stages of hepatic dedifferentiation included major metabolic pathways such as the TCA cycle, ketogenesis, the urea cycle and fatty acid metabolism.

To probe whether transcriptomic alterations were faithful markers of phenotypic changes during dedifferentiation, we performed whole-proteome analyses. Overall, we detected less expressed proteins than coding transcripts (2,356 proteins vs. 20,667 transcripts) most likely due to the low expression levels of many proteins such as transcription factors as well as the relatively lower sensitivity of mass spectrometry-based methods. To assess the agreement between responses on mRNA and protein level, we correlated transcriptomic and proteomic changes. Interestingly, while correlations were poor after 4 hours (r=0.16), they improved substantially after 24 hours (r=0.72; Figure 1D). Notably, abundances of most CYP proteins, such as CYP2A6, CYP2B6, CYP2C19 and CYP2D6 were only moderately affected after 24 hours of dedifferentiation in agreement with long half-lives of this class of proteins11,26, whereas their corresponding transcript levels were strongly reduced. The overall proteomic changes followed transcriptomic profiles with the exception of fatty acid β-oxidation, which was first detected at the proteomic levels (Figure 1C and Supporting Table 3). We concluded that changes in transcriptomic signatures translate into phenotypic changes during early hepatocyte dedifferentiation and are thus suitable markers to study underlying regulatory processes.

When we categorized differentially expressed transcripts into protein-coding genes, miRNAs, lncRNAs, snoRNAs and ribosomal genes (rRNAs and ribosomal proteins, we observed that changes in these ncRNA classes peaked at 4 hours, whereas an impact on coding genes was predominantly observed later (Figure 2). Furthermore, whereas protein-coding genes showed a tendency to be rather downregulated during dedifferentiation (52.4% downregulated), non-coding genes were predominantly upregulated (Figure 2C-F). Interestingly, among the different classes of ncRNAs, the dynamics and direction of regulation of lncRNAs Figure 2D) more closely resembled the temporal and directional profiles of coding genes (Figure 2B), possibly, at least in part, because of a positive correlation between the transcription of lncRNA and their proximal protein-coding genes27.

**miRNA levels are substantially reduced in primary hepatocytes upon small molecule inhibition of the miRNA machinery.**

Based on the dynamics and direction of transcriptomic changes, we hypothesized that modulations of the ncRNAome could be causal for alterations observed in protein-coding genes and thus for the loss of the hepatocyte phenotype. To test this hypothesis, we focused specifically on miRNAs since miRNA biogenesis and action is mediated by only few genes that constitute the miRNA processing machinery. We inhibited the miRNA pathway at two distinct nodes using two well-characterized, chemically distinct compounds, acriflavine (AF) and poly-L-lysine (PLL). While PLL is reported to inhibit the association of pre-miRNAs to Dicer, AF impairs RISC by inhibition of miRNA binding to AGO family proteins28. No toxicity of AF and PLL was detected at any of the concentrations tested after 4 hours (p>0.15 for all, Supporting Figure 2). After 24 hours, PLL affected viability only minimally even at high concentrations (viability PLLhi = 86%±4%), whereas AF was more toxic with increasing concentrations. Consequently, we chose to focus on samples treated with low AF (viability AFlow = 71%±4%) and high PLL concentrations, respectively.

First, we assessed the effect of AF and PLL on expression levels of a set of specific miRNAs with important roles in liver function (Figure 3A). Hepatic miRNAs miR-103 and miR-107 that regulate insulin sensitivity29 were upregulated during dedifferentiation, an effect that was inhibited by PLL and to a lesser extent by AF. Similarly, levels of the pro-proliferative miRNAs miR-21, miR-122 and miR-221, which target the cell cycle inhibitors *BTG2*, *HMOX1* and *CDKN1B*30-32, respectively, were rapidly increased, consistent with an initiation of the hepatic regeneration program. No significant changes were detected in the anti-proliferative miR-22 and miR-26a (p>0.05 for both miRs after 4 and 24h compared to t0, data not shown). Yet, levels of the anti-proliferative miRNA miR-33a, a direct inhibitor of *CDK6* and *CCND1*33 were massively increased during dedifferentiation. Importantly, PLL and AF generally reduced the burst of miRNA expression observed in untreated samples, indicating that small molecule inhibition of the miRNA machinery might be an effective means to reduce overall miRNA levels.

Next, we assessed the effect of AF and PLL on miRNA levels on a global scale and detected a decrease in overall miRNA expression levels (Figure 3B). While after 4h, 12% (AF) and 7% (PLL) of all expressed miRNA were downregulated >1.5-fold, after 24h 32% (AF) and 43% were downregulated upon AF and PLL treatment, respectively compared to control at the same time point (Figure 3C), thus confirming that inhibition of the miRNA machinery results in substantially reduced levels of mature miRNAs in the cell within the time frame studied.

**Inhibition of the miRNA machinery delays the loss of hepatic differentiation markers**

To address the impact of miRNA inhibition during hepatic dedifferentiation, we assessed whether AF- and PLL-mediated miRNA inhibition impacts hepatocyte dedifferentiation kinetics. We analyzed the changes in expression levels of 110 genes, including phase I and phase II enzymes, transporters, nuclear receptors and other genes with importance for hepatic functionality (Figure 4). We found that expression of these hepatic genes decreased rapidly in untreated hepatocytes with some genes being downregulated by up to 97% (*SLCO1B1* and *SLCO1B3*) after only 4 hours of culture (Figure 4B). Importantly, inhibition of the miRNA machinery largely mitigated the loss of marker gene expression (Figure 4 and qPCR validations in Supporting Figure 3). Consistent with the downregulation of hepatic genes during dedifferentiation, expression levels of the vast majority of these genes were found to be increased compared to untreated controls at the same time point (Figure 4C). We noticed that effect sizes of our treatments differed substantially between genes, as expression levels of *CYP3A4* and *HNF4A* increased only to a limited extent, whereas the effect on *CYP2C8* and *CYP2C9* was much more prominent (Figure 4A and Supporting Figure 3).

To substantiate the conceptual role of miRNAs in dedifferentiation, we specifically inhibited miR-103, a miRNA that was strongly affected by AF and PLL treatment, using specific antagomiRs (Supporting Figure 3). We found that expression of its *bona fide* target gene *CYP2C834* was significantly increased, thus providing evidence that candidate miRNA inhibition can contribute to a delay of dedifferentiation when only considering its particular target transcript subset.

We conclude that while the extent and kinetics to which hepatic marker genes are regulated by miRNAs can differ, inhibition of the miRNA machinery has overall profound effects on dedifferentiation at the molecular level.

**miRNA inhibition reduces overall hepatocyte dedifferentiation.**

To assess the impact of miRNA inhibition during dedifferentiation beyond alterations of expression patterns in hepatic markers, we correlated expression fold-changes for each gene after 4 hours and 24 hours of dedifferentiation in control with PLL- and AF-treated samples (Figure 5). The slope of the regression lines indicates the extent of dedifferentiation for a given treatment and time-point relative to control. After only 4 hours, transcriptomic signatures were significantly different between control and inhibitor-treated samples (p<0.0001, F-test comparing control and AF/PLL regression lines). In inhibitor-treated samples, expression levels were generally less affected compared to control (95% CI of regression slopes: (aPLL,4h) = 0.7-0.71; 95% CI(aAF,4h) = 0.76-0.76; Figure 5A,B), an effect became even more pronounced over time as transcriptomic fingerprints more closely resembled samples prior to dedifferentiation than dedifferentiated control samples after 24 hours of culture (95% CI(aPLL,24h) = 0.24-0.25; 95% CI(aAF,24h) = 0.27-0.28; Figure 5C,D). Furthermore, when considering only genes that were found to be differentially expressed during dedifferentiation (see Fig. 1), we found that changes in their gene expression signatures, indicative of dedifferentiation were drastically reduced (Supporting Figure 5).

While transcriptomes of treated and control samples correlated significantly (p<0.0001 for both AF and PLL, F-test), the expression levels of some individual genes differed drastically. When considering only those genes whose expression levels were increased >10-fold in miRNA-inhibitor treated samples, we found them to be enriched in both AF- and PLL-treated samples in acute phase response signaling, the complement system, FXR/RXR and PXR/RXR activation, thus suggesting prolongation of immune response signaling and a positive effect on liver specific functionality (see Supporting Table 4). Genes that were downregulated >10-fold in inhibitor-treated samples were enriched in adherence junction, actin cytoskeleton and ILK signaling. Again, very similar results were obtained using both AF and PLL.

Interestingly, transcriptomic changes in response to inhibition of the miRNA machinery were mostly symmetrically distributed in up- and downregulated genes compared to control (Supporting Fig. 6). Nevertheless, the fraction of genes that were downregulated less in treated compared to control samples was enriched especially after 24 hours (red columns, Supporting Fig. 6).

We then analyzed the effects of AF and PLL specifically on the miRNAome and associated pathways by matching upregulated miRNAs with their predicted target transcripts within the same experiment (Table 2). In control samples, metabolic pathways, protein processing in the endoplasmic reticulum and fatty acid metabolism were most significantly affected. Importantly, significantly fewer genes of the respective networks were targeted in AF- and PLL-treated samples in agreement with overall reduced dedifferentiation.

Combined, our data indicate that inhibition of the miRNA machinery results in drastic changes in the hepatic dedifferentiation program, strongly reducing the loss of hepatic markers and mitigating alterations in adherence junction signaling and cytoskeletal remodeling, suggesting a key role for miRNAs in driving the underlying molecular processes.

**Discussion**

Hepatocytes are very dynamic cells *in vivo* that can rapidly switch between non-dividing states during liver homeostasis and dividing states upon liver injury. During this process, they undergo a wide range of molecular changes including alterations in marker gene expression, indicating that they can transiently dedifferentiate into more progenitor-like states8,9. Following proliferation, cells redifferentiate and thus replenish the pool of mature hepatocytes within the regenerating organ9. Mechanistic understanding of how hepatocytes can alter their differentiation states can give valuable information for the generation of hepatocytes from stem cells. Dedifferentiation also occurs *in vitro* as rapid loss of marker gene expression and hepatic functionality are observed when PHH are placed in 2D culture. This loss of liver functions is detrimental in drug discovery and assessment programs where new chemical entities are tested e.g. for metabolism, toxicity, drug interactions and induction, as results form the basis for the development of clinical programs.

In this study we demonstrate that gradual changes in genes related to immunity and energy balance occurred during the first 4 hours of culture, followed by later changes in major metabolic pathways. Notably, the response at the proteomic level mostly overlapped and followed transcriptomic changes with respect to pathway enrichments, indicating that transcriptomic changes are overall faithful markers of phenotypic alterations in the early phases of hepatocyte dedifferentiation. Interestingly, transcriptomic and proteomic responses correlated only very weakly after 4 hours (r=0.16), probably at least in part due to the widespread transcriptomic remodeling, which has not been fully translated to the level of protein abundances. In contrast, correlations after 24 hours are significantly higher (r=0.72) and similar to values reported for murine liver (r=0.6 for mRNA vs. protein copy numbers)35.

When expression changes were resolved by gene class, the highest number of differentially expressed genes was detected after 4 hours of culture. Notably, the upregulation of ribosomal genes was paralleled by an activation of mTOR and EIF2 signaling, which primes cells for increased mRNA translation, foreshadowing a massive remodeling of cellular functionality and phenotypes36,37. Furthermore, the canonical function of snoRNAs is the 2’-O-methylation and pseudouridylation of ribosomal RNAs, again hinting at an overall translational activation18.

To functionally test the role of miRNAs as potential drivers of the dedifferentiation program, we used AF and PLL. PLL inhibits Dicer-dependent processing of pre-miRNA molecules into mature miRNAs, manifesting in reduced miRNA levels28, which is consistent the global reduction in miRNA levels (Figure 3). In contrast, AF blocks the binding of mature miRNA molecules to AGO family proteins and hence does not directly impact miRNA levels28. Yet, previous studies showed that unbound miRNAs are less stable than miRNAs bound to RISC38, which could explain the variability in expression levels of the different miRNAs. The extent of reduction in expression upon inhibitor treatment varied substantially between different miRNAs. While miR-33a levels were below detection limit upon PLL treatment already after 4 hours, levels of miR-21 were not affected, suggesting vastly different miRNA half-lives. This finding contrasts previous studies that reported miRNAs half-lives to range from hours to days, indicating that the inherent stability might differ miRNA species but also between primary cells during major remodeling processes and cell cultures in static conditions39. Notably, the slow kinetics of genetic or siRNA-based approaches for miRNA-inhibition combined with long half-lives of protein components of the miRNA machinery40 render such tools inadequate to inhibit miRNA action within the timeframe in which molecular changes occur. Therefore, small molecule inhibition presents currently the only viable option to perturb rapidly enough.

While hepatocytes proliferate *in vivo* after partial hepatectomy, dedifferentiation *in vitro* is not paralleled by hepatic proliferation. Even when cells are stimulated with growth factors, proliferation quickly ceases and cells enter cell cycle arrest41. This discrepancy between proliferative responses *in vivo* and *in vitro* correlates with the differences in response of miR-33 whose expression is reduced during liver regeneration, relieving inhibition of CDK6 and Cyclin D1 expression thereby supporting entry of cells into mitosis. In contrast, miR-33a expression is strongly increased *in vitro* (Figure 3A), hampering cell cycle entry. Thus, inhibition of miR-33a might present a novel approach to stimulate proliferation of primary hepatocytes *in vitro.*

Importantly, analyses of expression kinetics of 110 hepatic genes revealed that their downregulation was mostly reduced with both miRNA inhibitors, yet to varying extents (Figure 4 and Supporting Fig. 3). While the decrease in e.g. *CYP2A6*, *CYP2C8*, *CYP2C9*, *CYP2D6* and *SLC22A1* expression was strongly reduced, only minor elevations of transcript levels were observed for *CYP3A4*. Our results are in agreement with previous experimental findings showing that *CYP2C8* (miR-103/107) and *CYP2C9* (miR-128) are strongly regulated by miRNAs34,42. Furthermore, a recent screen for miRNAs as modulators of *CYP3A4* activity revealed only minor inhibition43 consistent with the low but significant increase in *CYP3A4* transcript levels observed here. To validate these findings, we inhibited miR-103 using a specific antagomiR and found that its *bona fide* target gene *CYP2C8* was upregulated accordingly during dedifferentiation (Supporting Figure 4). These experimental indications about the extent to which miRNAs regulate ADME gene expression further incentivizes their therapeutic targeting and warrants investigations of the impact of miRNAs on the disposition of co-administered drugs44. Yet, further studies are required to quantify the recruitment of specific miRNAs to the RISC, as bound miRNAs might be more faithful reporters for regulatory load during liver regeneration than overall transcriptional levels45.

Combined, our data indicate that (i) an upregulation of a multitude of miRNAs precedes the loss of hepatic marker gene expression and (ii) that this dedifferentiation is diminished when the miRNA pathway is either generally inhibited or when candidate miRNAs are blocked in a targeted approach. Importantly though, not all hepatic markers that we analyzed responded to miRNA inhibition with similar magnitude indicating that also other regulatory mechanisms such as short transcript half-lives potentially contribute to a rapid downregulation of transcript levels.

When we correlated expression fold-changes in control and miRNA inhibitor-treated samples, we found that the ameliorating effect on dedifferentiation increased after 24 hours, possibly due to indirect effects such as the regulation of core transcription factors (Figure 5). Most considerably “rescued” pathways by miRNA inhibition were complement system and cytokine signaling, cytoskeleton, cell adhesion, and hepatic expression programs such as PXR/RXR activation (Figure 5C,D), thus mirroring deregulated pathways during dedifferentiation and indicating an overall improvement of hepatic phenotype. While the data presented here indicates that miRNA changes constitute an integral part of the hepatic dedifferentiation program, the upstream cues that trigger the initiation of dedifferentiation, remain to be elucidated. To this end, a variety of stimuli have been suggested, including harsh hepatocyte isolation conditions as such, serum depletion, alterations in cell-ECM or cell-cell contacts and exposure to non-physiological stiffness of culture substratum46,47. However, as hepatocytes retain their functionality when cultured as 3D spheroids in serum-free conditions48, perturbations of cell-ECM or cell-cell contacts and exposure to non-physiological stiffness of culture substratum appear to be most likely causes.

The data presented here might exemplify a more general biological principle of dynamic cellular adaptation. miRNAs might serve as the tool of choice for the cell to quickly degrade particular mRNA and/or inhibit their translation, especially those with a long half-life, and thus facilitate expeditious remodeling of the transcriptomic inventory when rapid adjustments are needed in response to changes in environment or specific signaling cues as seen in other contexts, such as T-cell activation49. Furthermore, as miRNAs can have pleiotropic targets thereby diversifying an incoming stimulus into a wide range of downstream targets, thus serving as a molecular signal amplifier.

In conclusion, our results indicate a novel role for miRNAs in hepatic processes and implicate them as important drivers of hepatic dedifferentiation. As such, these findings are of importance for understanding mechanisms of stem cell differentiation into hepatocytes as well as for liver regeneration, during which similar dedifferentiation processes might occur *in vivo*. Furthermore, the data presented here might highlight a more wide-spread miRNA-mediated dynamic control of transcriptional profiles that warrants further investigations.

**Acknowledgements**

We thank Drs. Roz Jenkins and Joanne Walsh for support with proteomic analyses.

**Supporting Information**

Additional Supporting information can be found online.

**Figure 1: Profiling of early events in hepatic dedifferentiation on transcriptomic and proteomic level reveals overall molecular rearrangements.** (**A**) Heatmap visualization of mean-centered, sigma-normalized expression data of differentially expressed genes during the first 24 hours of hepatocyte dedifferentiation (n=4,042, FDR=0.01) reveals an early response in which expression changes accumulate progressively during the first 4 hours and (ii) a later response in which a different set of genes was affected. Numbers in the colored circles indicate the respective hepatocyte donor (Table 1). (**B**) Principle component analysis of differentially expressed genes shown in **A** resulted in the identification of two orthogonal components for early and late transcriptomic changes. (**C**) Pathway analysis of differentially expressed genes revealed the temporal order of events. Pathways identified as differentially regulated in at least 2 consecutive time points with p<0.05 on transcriptomic (blue) and proteomic level (red) are shown. (**D**) Scatter plots showing the correlations between mean changes in mRNA levels and the corresponding average changes in protein abundances after 4 hours and 24 hours in culture. The mean of 3 donors is plotted.

**Figure 2: Early changes in non-coding RNAs precede rearrangements of the coding transcriptome during hepatocyte dedifferentiation**. (**A**) Stacked column plot visualizing the number of up- and downregulated genes at each time point compared to t0. Coding genes are shown in blue, non-coding genes in grey. Small pie charts associated to each column indicate the relative fractions of differentially expressed non-coding RNAs at the respective time point categorized by gene class. Note that the highest number of differentially expressed genes was found after 4 hours and was dominated by upregulated non-coding RNAs. (**B**-**E**) Stacked column plots showing the profiles of transcriptomic changes resolved by gene class and up- and downregulation (dark and light hue, respectively) into protein-coding genes (**B**), miRNAs (**C**), lncRNAs (**D**), snoRNAs (**E**) and ribosomal genes (**F**). y-axis indicates differentially expressed genes. While protein-coding genes were up- and downregulated, non-coding genes had a strong bias for upregulation especially at early time points.

**Figure 3: miRNA expression during hepatocyte dedifferentiation can be inhibited using small molecule inhibitors.** The miRNA machinery was inhibited using acriflavine (AF) and poly-L-lysine (PLL). All expression levels were normalized to expression prior to dedifferentiation (t0). (**A**) Expression of all six miRNAs shown were elevated during dedifferentiation in control samples (blue). This increase in miRNA levels was mostly inhibited dose-dependently by AF (red) and PLL treatment (green). Inhibitor-treated samples were compared with the corresponding controls at the same time point using heteroscedastic two-tailed t-tests. Error bars indicate s.e. \* indicates p<0.05, \*\* indicates p<0.01. n.d. indicates expression below detection limit. N=6 experiments for controls and 3 for inhibitor-treated samples (**B, C**) Transcriptomic assessment of miRNA levels upon AF- and PLL-treatment. (**B**) Heatmap displaying expression changes of all detected miRNAs. (**C**) Column plot showing the fraction of expressed miRNAs that were downregulated more than 1.5-fold compared to control at the same time point. In total n=210 different miRNAs were robustly detected in all samples.

**Figure 4:** **Inhibition of the miRNA machinery ameliorates changes in hepatic genes during hepatic dedifferentiation**. (**A**) Heatmap visualization of mean-centered, sigma-normalized expression data of 110 genes with importance for hepatic functionality. Note that while many hepatic genes are rapidly lost in control samples, treatment with AF and PLL overall decreases this effect. (**B**, **C**) Dot plot representations visualizing the change of expression of the same 110 hepatic genes compared to timepoint 0 (**B**) or to the corresponding control at the same time point (**C**). Notably, *CYP2A6*, a specialized indicator of hepatic differentiation11, is upregulated 8- and 26-fold in AF and PLL-treated samples after 24h, respectively. FC = fold change.

**Figure 5: Evaluation of overall transcriptomic changes in response to miRNA inhibitors reveals drastically reduced dedifferentiation**. Scatter log-plots of transcriptomic changes (n=61,933 gene products) in control samples versus changes in AF- or PLL-treated cultures after 4 h (**A**-**B**) and 24 h (**C**-**D**). Red and green dots highlight genes that are up- or downregulated >10-fold under treatment, respectively. These form the basis for the analysis of most affected pathways shown in red and green inlet boxes. Solid red lines indicate complete dedifferentiation in control samples (slope a=1). Dashed red lines indicate computed regression lines. Note that regression line slopes (ainh) can be interpreted as the extent of dedifferentiation and were <1 for all time points and treatments, indicating decreased overall dedifferentiation at the systems level. Values for r indicate Pearson correlation coefficients.

**Reference**s

1 Michalopoulos, G.K. Liver regeneration. *Journal of Cellular Physiology* **213**, 286-300 (2007).

2 Fausto, N., Campbell, J.S. & Riehle, K.J. Liver regeneration. *Hepatology* **43**, S45-S53 (2006).

3 Yovchev, M. I. *et al.* Identification of adult hepatic progenitor cells capable of repopulating injured rat liver. *Hepatology* **47**, 636-647 (2007).

4 Kordes, C. & Häussinger, D. Hepatic stem cell niches. *Journal of Clinical Investigation* **123**, 1874-1880 (2013).

5 Evarts, R.P., Nagy, P., Marsden, E. & Thorgeirsson, S.S. A precursor-product relationship exists between oval cells and hepatocytes in rat liver. *Carcinogenesis* **8**, 1737-1740 (1987).

6 Schaub, J.R., Malato, Y., Gormond, C. & Willenbring, H. Evidence against a Stem Cell Origin of New Hepatocytes in a Common Mouse Model of Chronic Liver Injury. *Cell Reports* **8**, 933-939 (2014).

7 **Yanger, K., Knigin, D**. *et al.* Adult Hepatocytes Are Generated by Self-Duplication Rather than Stem Cell Differentiation. *Cell Stem Cell* **15**, 340-349, (2014).

8 **Yanger, K., Zong, Y**. *et al.* Robust cellular reprogramming occurs spontaneously during liver regeneration. *Genes & Development* **27**, 719-724, (2013).

9 Tarlow, B.D. *et al.* Bipotential Adult Liver Progenitors Are Derived from Chronically Injured Mature Hepatocytes. *Stem Cell* **15**, 605-618 (2014).

10 Chen, Y., Wong, P.P., Sjeklocha, L., Steer, C.J. & Sahin, M.B. Mature hepatocytes exhibit unexpected plasticity by direct dedifferentiation into liver progenitor cells in culture. *Hepatology* **55**, 563-574 (2012).

11 Rowe, C. *et al.* Proteome-wide analyses of human hepatocytes during differentiation and dedifferentiation. *Hepatology* **58**, 799-809 (2013).

12 Baker, T.K. *et al.* Temporal Gene Expression Analysis of Monolayer Cultured Rat Hepatocytes. *Chemical Research in Toxicology* **14**, 1218-1231 (2001).

13 Cech, T.R. & Steitz, J.A. The Noncoding RNA Revolution— Trashing Old Rules to Forge New Ones. *Cell* **157**, 77-94 (2014).

14 Wilczynska, A. & Bushell, M. The complexity of miRNA-mediated repression. *Cell Death and Differentiation* **22**, 22-33 (2015).

15 Gamazon, E.R. *et al.* A genome-wide integrative study of microRNAs in human liver. *BMC Genomics* **14**, 395 (2013).

16 Kim, N. *et al.* Expression profiles of miRNAs in human embryonic stem cells during hepatocyte differentiation. *Hepatology Research* **41**, 170-183 (2011).

17 Clouet d’Orval, B., Bortolin, M.L., Gaspin, C. & Bachellerie, J.P. Box C/D RNA guides for the ribose methylation of archaeal tRNAs. The tRNATrp intron guides the formation of two ribose-methylated nucleosides in the mature tRNATrp. *Nucleic Acids Research* **29**, 4518-4529 (2001).

18 Decatur, W.A. & Fournier, M.J. rRNA modifications and ribosome function. *Trends in Biochemical Sciences* **27**, 344-351 (2002).

19 Taft, R.J. *et al.* Small RNAs derived from snoRNAs. *RNA* **15**, 1233-1240 (2009).

20 **Kishore, S., Kanna, A**. *et al.* The snoRNA MBII-52 (SNORD 115) is processed into smaller RNAs and regulates alternative splicing. *Human Molecular Genetics* **19**, 1153-1164 (2010).

21 **Ender, C., Krek, A.** *et al.* A Human snoRNA with MicroRNA-Like Functions. *Molecular Cell* **32**, 519-528 (2008).

22 **Sharma, E., Sterne-Weiler, T**., O’Hanlon, D. & Blencowe, B.J. Global Mapping of Human RNA-RNA Interactions. *Molecular Cell* **62**, 618-626, (2016).

23 Kung, J.T., Colognori, D. & Lee, J.T. Long Noncoding RNAs: Past, Present, and Future. *Genetics* **193**, 651-669 (2013).

24 Strom, S.C. *et al.* Use of human hepatocytes to study P450 gene induction. *Methods in Enzymology* **272**, 388-401 (1996).

25 Wang, J., Duncan, D., Shi, Z. & Zhang, B. WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013. *Nucleic Acids Research* **41**, W77-W83 (2013).

26 Yang, J. *et al.* Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. *Current Drug Metabolism* **9**, 384-394 (2008).

27 **Andersson, R., Gebhard, C**. *et al.* An atlas of active enhancers across human cell types and tissues. *Nature* **507**, 455-461, (2014).

28 Watashi, K., Yeung, M.L., Starost, M.F., Hosmane, R.S. & Jeang, K.T. Identification of Small Molecules That Suppress MicroRNA Function and Reverse Tumorigenesis. *Journal of Biological Chemistry* **285**, 24707-24716 (2010).

29 Trajkovski, M. *et al.* MicroRNAs 103 and 107 regulate insulin sensitivity. *Nature* **474**, 649-653 (2011).

30 Liu, M. *et al.* Regulation of the cell cycle gene, BTG2, by miR-21 in human laryngeal carcinoma. *Cell Research* **19**, 828-837 (2009).

31 John, K. *et al.* MicroRNAs play a role in spontaneous recovery from acute liver failure. *Hepatology* **60**, 1346-1355 (2014).

32 Fornari, F. *et al.* MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. *Oncogene* **27**, 5651-5661 (2008).

33 **Cirera-Salinas, D., Pauta, M**. *et al.* Mir-33 regulates cell proliferation and cell cycle progression. *Cell Cycle* **11**, 922-933, (2012).

34 **Zhang, S.Y., Surapureddi, S**., Coulter, S., Ferguson, S.S. & Goldstein, J.A. Human CYP2C8 Is Post-Transcriptionally Regulated by MicroRNAs 103 and 107 in Human Liver. *Molecular Pharmacology* **82**, 529-540, (2012).

35 Azimifar, S.B., Nagaraj, N., Cox, J. & Mann, M. Cell-Type-Resolved Quantitative Proteomics of Murine Liver. *Cell Metabolism* **20**, 1076-1087 (2014).

36 Xiao, L. & Grove, A. Coordination of Ribosomal Protein and Ribosomal RNA Gene Expression in Response to TOR Signaling. *Current Genomics* **10**, 198-205 (2009).

37 Kimball, S.R. Eukaryotic initiation factor eIF2. *The International Journal of Biochemistry & Cell Biology* **31**, 25-29 (1999).

38 Diederichs, S. & Haber, D.A. Dual Role for Argonautes in MicroRNA Processing and Posttranscriptional Regulation of MicroRNA Expression. *Cell* **131**, 1097-1108 (2007).

39 **Gantier, M.P., McCoy, C.E.** *et al.* Analysis of microRNA turnover in mammalian cells following Dicer1 ablation. *Nucleic Acids Research* **39**, 5692-5703 (2011).

40 **Olejniczak, S.H., La Rocca, G.,** Gruber, J. J. & Thompson, C. B. Long-lived microRNA-Argonaute complexes in quiescent cells can be activated to regulate mitogenic responses. *PNAS* **110**, 157-162 (2013).

41 Runge, D.M. *et al.* Epidermal growth factor- and hepatocyte growth factor-receptor activity in serum-free cultures of human hepatocytes. *Journal of Hepatology* **30**, 265-274 (1999).

42 Yu, D. *et al.* Suppression of CYP2C9 by MicroRNA hsa-miR-128-3p in Human Liver Cells and Association with Hepatocellular Carcinoma. *Scientific Reports* **5**, 8534-8539 (2015).

43 **Wei, Z., Jiang, S**. *et al.* The Effect of microRNAs in the Regulation of Human CYP3A4: a Systematic Study using a Mathematical Model. *Scientific Reports* **4**, 1-7 (2014).

44 Li, Z. & Rana, T.M. Therapeutic targeting of microRNAs: current status and future challenges. *Nature Genetics* **13**, 622-638 (2014).

45 **Schug, J., McKenna, L.B**. *et al.* Dynamic recruitment of microRNAs to their mRNA targets in the regenerating liver. *BMC Genomics* **14**, 264 (2013).

46 Elaut, G. *et al.* Molecular mechanisms underlying the dedifferentiation process of isolated hepatocytes and their cultures. *Current Drug Metabolism* **7**, 629-660 (2006).

47 Godoy, P. *et al.* Extracellular matrix modulates sensitivity of hepatocytes to fibroblastoid dedifferentiation and transforming growth factor β-induced apoptosis. *Hepatology* **49**, 2031-2043 (2009).

48 **Bell, C.C., Hendriks, D.F., Moro, S.M.** *et al.* Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease. *Scientific Reports*, 1-13 (2016).

49 Bronevetsky, Y. *et al.* T cell activation induces proteasomal degradation of Argonaute and rapid remodeling of the microRNA repertoire. *Journal of Experimental Medicine* **210**, 417-432 (2013).